Jeanmarie Guenot is an entrepreneur in the pharmaceutical and biotechnology field. She has over two decades’ experience in this industry and is an expert at what she does. She has worked with many companies, both private and public, and in different stages of the business lifecycle. She is, therefore, well versed in the management and operation of different types of companies. Besides management, Dr. Guenot has worked in the research and development department of various pharmaceutical companies. Some of the companies she has worked with include PDL BioPharma and Hoffman-La Roche. She holds an MBA from the University of Pennsylvania and a PhD from the University of California.
Dr. Guenot founded a company incubator known as SKS Ocular. Its main focus was the provision of solutions for various ophthalmic issues. She also founded Guenot LLC, a company that provides pharmaceutical and biotech companies with excellent consultation services including financial advice, project management and business restructuring advice among other services. Jeanmarie Guenot is currently the president and CEO of Amphivena Therapeutics.
Amphivena Therapeutics developing a new drug
Amphivena Therapeutics is a company that develops immunotherapies for cancer treatment. It is based in San Francisco, CA and has been in operation since July 2013.Under Dr. Guenot’s leadership, the company strives to improve the lives of cancer patients by developing treatments for various cancers, especially those affecting the blood. Amphivena is performing exceptionally well in the pharmaceutical industry, carrying out extensive high-quality research on different cancers. The company’s latest development is a new drug intended to be used in the treatment of acute myeloid leukemia (AML). It is currently in the clinical development stage and Amphivena hopes to launch it as soon as it is approved for use by the FDA.
Dr. Guenot’s expertise in the pharmaceutical industry has proven to be a valuable asset in her current position at Amphivena Therapeutics. Her background in research and development makes her well suited for the position. Jeanmarie’s excellent leadership skills are what have enabled the company to make such remarkable progress in the development of treatments for blood cancer in just three and a half years. Follow more of Jeanmarie Guenot and Amphivena’s mission at the official website.